Eli Lilly’s Retevmo Approved for Lung and Thyroid Cancers

The FDA has granted accelerated approval to Eli Lilly’s Retevmo (selperactinib) for patients with advanced RET-driven, non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers.

Retevmo is a selective RET kinase inhibitor that can block mutations which account for the majority of medullary thyroid cancers.

The fast-track approval was based on the results of a phase 1/2 clinical trial in more than 700 patients, the largest-ever study of patients with RET-driven cancers.

Retevmo was granted priority review, breakthrough therapy and orphan drug designations.